Since its foundation in 1997, GENESIS Pharma has been a leading biopharmaceutical company, headquartered in Greece. From 2006 to 2008, the company's consolidated turnover increased by an average of 20% annually, reaching €223,4 million in 2008, compared to €172,4 million in 2007 and €154,4 million in 2006.

With its core business activity focusing on the sales, marketing and distribution of biopharmaceutical products, GENESIS Pharma has developed strategic alliances with 13 leading companies in the global biotechnology market, such as Amgen, Biogen Idec, Celgene, Cephalon, Pharmamar, Shire and Vifor.

The company has launched and marketed a unique portfolio of innovative biopharmaceutical products in Greece and Cyprus, principally within the specialty therapeutic areas of the Central Nervous System, Haematology, Nephrology and Oncology. Many of the company's products treat rare chronic or life-threatening diseases and most of them address previously unmet or underserved clinical needs.